Skip to content
RDL Network logo
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the <scp>BOSTON</scp> trial — María‐Victoria Mateos (2024) | RDL Network